BamSEC and AlphaSense Join Forces
Learn More

Revolution Medicines Inc

NASDAQ: RVMD    
Share price (12/20/24): $44.06    
Market cap (12/20/24): $7.412 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.3
from 10-Q 21 pages Revolution Medicines, Inc. Employment Agreement
12/34/56
EX-10.2
from 10-Q 20 pages Revolution Medicines, Inc. Employment Agreement
12/34/56
EX-10.1
from 10-Q 25 pages Sixth Amendment to Lease
12/34/56
EX-10.3
from 10-Q 21 pages Revolution Medicines, Inc. Employment Agreement
12/34/56
EX-10.2
from 10-Q 20 pages Revolution Medicines, Inc. Employment Agreement
12/34/56
EX-10.1
from 10-Q 25 pages Sixth Amendment to Lease
12/34/56
EX-10.1
from 10-Q 6 pages Revolution Medicines, Inc. Non-Employee Director Compensation Program as Amended, March 21, 2024
12/34/56
EX-10.3
from 10-Q 5 pages Fifth Amendment to Lease
12/34/56
EX-10.2
from 8-K 8 pages Form of Stockholder Lock-Up Agreement July 31, 2023
12/34/56
EX-10.1
from 8-K 14 pages Form of Company Stockholder Voting Agreement
12/34/56
EX-10
from 10-Q 15 pages Fourth Amendment to Lease
12/34/56
EX-10
from 10-Q 6 pages Revolution Medicines, Inc. Non-Employee Director Compensation Program as Amended, March 23, 2023
12/34/56
EX-10.1
from 8-K 3 pages First Amendment to Employment Agreement
12/34/56
EX-10.3
from 10-Q 21 pages Revolution Medicines, Inc. Employment Agreement
12/34/56
EX-10.2
from 10-Q 21 pages Revolution Medicines, Inc. Employment Agreement
12/34/56
EX-10.1
from 10-Q 5 pages Revolution Medicines, Inc. Non-Employee Director Compensation Program as Amended, March 10, 2022
12/34/56
EX-10.1
from 10-Q 13 pages Third Amendment to Lease
12/34/56
EX-10.2
from 10-Q 3 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. August 5, 2021 1.rmc-4630-03 – Amgen Doublet
12/34/56
EX-10.1
from 10-Q 5 pages Revolution Medicines, Inc. Non-Employee Director Compensation Program as Amended, June 22, 2021
12/34/56
EX-10.12
from S-1 3 pages Revolution Medicines, Inc. Non-Employee Director Compensation Program as Amended, June 17, 2020
12/34/56